

RESPONDER CELLS: RAT SPLEEN CELLS
STIMULATOR CELLS: HUMAN HEPATOCYTES

SPLEEN(S): SPLEEN CELLS FROM RATS
TREATED WITH SALINE WHEN THEY WERE
FETUSES.

HEP: IRRADIATED HUMAN HEPATOCYTES.

SPLEEN(IU): SPLEEN CELLS FROM RATS
TOLERIZED BY INTRAUTERINE INJECTION OF
HUMAN HEPATOCYTE LYSATES.

SPLEEN(IU/IS): SPLEEN CELLS FROM RAT
TOLERIZED BY INTRAUTERINE INJECTION OF
HUMAN HEPATOCYTE LYSATES FOLLOWED
BY INTRASPLENIC TRANSPLANTATION OF
HUMAN HEPATOCYTES AFTER BIRTH.

FIG.1

1 2 3 4 5

FIG.2




FIG.3



FIG. 4A




FIG. 4B




FIG. 4C




FIG. 4D

208230-78/03E660




FIG.5



FIG. 6A




FIG. 6B



FIG. 6C




FIG. 6D




FIG.7

Time course of human albumin and HBV expression

Anti Human Albumin

Anti Hepatitis B Surface Antigen

1 week




FIG. 8A




FIG. 8B

6 weeks




FIG. 8C




FIG. 8D

20230718 13:05:50

05930784-032302

14 weeks



FIG.8E



FIG.8F

Rat CA2
Hepatocytes
Plus HBV

Anti Human Albumin



FIG.9A

Anti Hepatitis B Surface Antigen



FIG.9B

Rat CA3
Hepatocytes
alone



FIG.9C




FIG.9D

Rat CA5
HBV alone




FIG.9E



FIG.9F

Rat CA2
minus primary Ab




FIG.9G



FIG.9H

RT-PCR Human Albumin mRNA



- 1: 1000 bp ladder
- 2: Rat RNA
- 3: Human RNA
- 4: HepG2.2.15 RNA
- 5: Rat CA1 — Human hepatocytes + HBV
- 6: Rat CA2 — Human hepatocytes + HBV
- 7: Rat CA3 — Human hepatocytes
- 8: Rat CA4 — Human hepatocytes
- 9: Rat CA5 — HBV
- 10: Rat CA6 — HBV
- 11: Rat CA7 — Saline

FIG.10

RT-PCR Human Albumin RNA





FIG.11A

RT-PCR HBV RNA



- 1: 1 kbp ladder
- 2: Rat liver RNA
- 3: Human liver RNA
- 4: HepG2.2.15 RNA
- 5: Rat CA2 - Human hepatocytes + HBV,
1 week post
- 6: Rat CA2 - 6 weeks post
- 7: Rat CA2 - 14 weeks post

FIG.11B





FIG.12

Hepatocytes
plus HBV

1 week


FIG.13A



Hepatocytes
plus HBV

6 weeks


FIG.13B



Hepatocytes
plus HBV

14 weeks

FIG.13C



09930781-032802

Hepatocytes
plus HBV

1 week




FIG.14A

Hepatocytes
plus HBV

6 weeks




FIG.14B

Hepatocytes
plus HBV

14 weeks




FIG.14C




FIG. 15



FIG. 16A




FIG. 16B




FIG. 16C




FIG. 16D




FIG. 16E




FIG. 16F




FIG.17A



FIG.17B




FIG.17C




FIG.17D




FIG.18A




FIG.18B




FIG.19A




FIG.19B





FIG.20

FIG. 21



203220-18/03/00





FIG. 22

Day 1



X125

FIG. 23A




X250

FIG. 23B



X125

FIG. 23C



X250

FIG. 23D

Day 7



X125

FIG. 23E



X250

FIG. 23F

09930781-03802

FIG. 24A




FIG. 24B



FIG. 24C



FIG. 24D






FIG. 25

FIG. 26A




FIG. 26B

palb3 plasmid

100 pg 10 pg 1 pg



Arbitrary Units



FIG. 26C

FIG. 27A




FIG. 27C





FIG. 27B

09930781-032802




FIG. 28

human Albumin



FIG. 29A

BrdU




FIG. 29B

Tolerized
with T3
no trans-
plantation



FIG. 29C




FIG. 29D

Tolerized
with T3
and trans-
plantation




FIG. 29E




FIG. 29F

Control
no T3
no trans-
plantation

0930791.03802





FIG. 30


Time Post-HCV Inoculation (weeks)

2 4 6 8 12 16

Huh7



HepG2



PHH



PBS




FIG. 31

FIG. 32

Time Post-HCV Inoculation (weeks)

4

6

8

12

16

Huh7




+



+



+



+

HepG2



+

PHH



+

PBS



-



-



-



-



-